Osmosis Investment Management UK Ltd Invests $895,000 in IQVIA Holdings Inc. $IQV

Osmosis Investment Management UK Ltd acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,630 shares of the medical research company’s stock, valued at approximately $895,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Apella Capital LLC raised its position in IQVIA by 5.1% in the first quarter. Apella Capital LLC now owns 1,196 shares of the medical research company’s stock valued at $211,000 after purchasing an additional 58 shares during the period. Quadrant Capital Group LLC grew its holdings in shares of IQVIA by 1.3% during the 4th quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company’s stock worth $1,080,000 after purchasing an additional 60 shares during the period. Private Advisor Group LLC increased its position in shares of IQVIA by 1.0% during the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock worth $1,163,000 after purchasing an additional 63 shares during the last quarter. Breakwater Capital Group raised its holdings in IQVIA by 3.2% in the 2nd quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock valued at $401,000 after buying an additional 64 shares during the period. Finally, Keybank National Association OH lifted its position in IQVIA by 0.7% in the fourth quarter. Keybank National Association OH now owns 9,103 shares of the medical research company’s stock valued at $2,052,000 after buying an additional 67 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

NYSE IQV opened at $260.30 on Tuesday. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The company has a market cap of $42.85 billion, a P/E ratio of 32.30, a P/E/G ratio of 2.21 and a beta of 1.18. The stock has a 50-day moving average of $214.97 and a two-hundred day moving average of $187.62. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $261.88.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. During the same quarter in the prior year, the company earned $2.81 earnings per share. The business’s quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its Board of Directors has authorized a stock buyback program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy up to 6.8% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,000 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the sale, the insider directly owned 20,999 shares in the company, valued at $5,232,110.84. This represents a 19.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider W Richard Staub sold 5,500 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the transaction, the insider directly owned 13,312 shares of the company’s stock, valued at $3,097,436.16. This represents a 29.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 12,913 shares of company stock valued at $3,098,793 in the last quarter. Corporate insiders own 1.70% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of recent analyst reports. BMO Capital Markets lifted their price target on shares of IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. JPMorgan Chase & Co. upped their price objective on shares of IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Barclays reaffirmed an “overweight” rating on shares of IQVIA in a research report on Tuesday, July 28th. Mizuho boosted their target price on IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Finally, William Blair upgraded IQVIA to a “strong-buy” rating in a research note on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $241.88.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.